We’re moving from narrow growth powered by big AI companies to earnings-driven returns from a wider array of sectors,” says ...

While choking can happen to anyone at any time, certain people are at higher risk, including people with neurological ...

From dropping out of film school to leading the Canadian firm’s bold public offering, the tech trailblazer is no stranger to ...

The current OpenJDK 26 is strategically important and not only brings exciting innovations but also eliminates legacy issues ...

Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100 million for its AI-powered drug discovery operations. Incubated by Flagship Pioneering, Generate applies AI ...

Generate:Biomedicines is hoping to raise up to $425 million via a Nasdaq IPO, with the proceeds needed to bankroll its lead antibody through respiratory disease trials. The Flagship Pioneering-founded ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Add Yahoo as a preferred source to see more of our stories on Google. Photo Credit: iStock Solar energy is getting a bipartisan jolt in Virginia. Republican Delegate Delores Oates has proposed ...

Leeron is a New York-based writer who specializes in covering technology for small and mid-sized businesses. Her work has been featured in publications including Bankrate, Quartz, the Village Voice, ...